Moderna (MRNA) and Australia Collaborate to Bring mRNA Manufacturing to Australia

Moderna's (MRNA) COVID-19 Vaccine Manufactured in Korea by Samsung Granted Marketing Authorization from Ministry of Food and Drug Safety of Korea

Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Spikevax®, Moderna's COVID-19 vaccine (mRNA-1273) manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.

This marketing authorization obtained by Moderna Korea officially allows the Moderna's COVID-19 vaccine manufactured at Samsung Biologics' local pharmaceutical production facilities to be distributed within Korea and... More

Popular stocks with increasing volume: T LCID MRNA PTON EWT HOG

Popular stocks with increasing volume: T LCID MRNA PTON EWT HOG

Popular stocks with increasing volume: LCID MRNA PTON EWT HOG ATOS NAT EWJ

Popular stocks with increasing volume: LCID MRNA PTON EWT HOG ATOS NAT EWJ

Moderna (MRNA) Stock Gains While Street Analysts Discuss What Comes Next Following Early Flu Vaccine Data

Analysts continue to discuss early data for Modernas (NASDAQ: MRNA) flu vaccine, released by the company last week.

Morgan Stanley analyst Matthew Harrison described the early flu vaccine data as undifferentiated on Friday.

We believe the market was looking for data which supported clearly better efficacy, such that today's results are likely to pressure MRNA, the analyst said in a client note Friday.

In a follow-up note released today, Harrison discusses the next catalysts for Moderna going forward. The analyst rates MRNA shares as Equal Weight with a $313.00 per share price... More

Moderna (MRNA) Continues to Grind off Lows, Remains Down 5.5%

Moderna (NASDAQ: MRNA) continues to grind off lows, shares remain down 5.5%. A U.K. study that boosters give 70-75% Omicron protection is helping.

Boosters give 70-75% Omicron protection, U.K. study shows - Bloomberg

Boosters give 70-75% Omicron protection, U.K. study shows - Bloomberg

Moderna (MRNA) Stock Down 11% on Likely Disappointing Flu Vaccine Data, Seen as 'Undifferentiated' by Morgan Stanley

Morgan Stanley analyst Matthew Harrison briefly weighed in on the preliminary flu vaccine data released by Moderna (NASDAQ: MRNA) this morning.

Modernas mRNA-1010 vaccine candidate successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults, the company said in a press... More

Moderna (MRNA) opens down 12% as flu data called 'undifferentiated'

Moderna (NASDAQ: MRNA) opens down 12% as flu data called 'undifferentiated'.

Pre-Open Stock Movers 12/10: (CNTX) (AI) (ORCL) Higher; (ANGN) (CCNC) (MRNA) Lower (more...)

Pre-Open Stock Movers

Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) 22.6% LOWER; announced results from the exploratory phase-II GUARD trial of Angions ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.

Context Therapeutics Inc. (Nasdaq:... More

Moderna (MRNA) to Supply an 20M Doses of COVID-19 Vaccine to COVAX for 2021

Moderna (Nasdaq: MRNA) announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun.

These doses are included in Modernas previously announced agreement with Gavi and were originally scheduled for delivery in the first quarter of 2022. Given the acceleration into 2021, Moderna expects to supply up to 96.5 million doses in the first quarter of 2022 and an... More